Literature DB >> 31989349

Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Kazuaki Takahashi1, Masataka Takenaka2, Ayako Kawabata2, Nozomu Yanaihara2, Aikou Okamoto2.   

Abstract

Ovarian clear cell carcinoma (OCCC), with unique clinical and molecular characteristics compared with other histological types of epithelial ovarian cancer (EOC), behaves like a distinct entity and has a poorer prognosis than other EOC types, especially in advanced stages. In addition, OCCC comprises approximately 27% of all EOC cases in Japan, compared with 12% in Western countries. Historically, patients with OCCC have been eligible for chemotherapeutic and surgical trials of EOC. It has been difficult to evaluate the specific impact of these trials on the prognosis of women with OCCC because of its rarity and unique molecular characteristics. Recent studies of OCCC revealed significant molecular variations related to carcinogenesis and molecular targets that could directly facilitate patient stratification and subsequent precision medicine. Thus, treatment strategies specific for OCCC based on its clinical and molecular characteristics are urgently needed. In this review, we highlight the management and treatment of OCCC from clinical aspects.

Entities:  

Keywords:  ARID1A; Deep venous thrombosis; Endometriosis; Ovarian clear cell carcinoma; Primary debulking surgery

Mesh:

Year:  2020        PMID: 31989349     DOI: 10.1007/s10147-020-01625-w

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  56 in total

1.  Surgical and medical treatment of clear cell ovarian cancer: results from the multicenter Italian Trials in Ovarian Cancer (MITO) 9 retrospective study.

Authors:  Francescapaola Magazzino; Dionyssios Katsaros; Alessandro Ottaiano; Angiolo Gadducci; Carmela Pisano; Roberto Sorio; Emanuela Rabaiotti; Giovanni Scambia; Gennaro Cormio; Luca Scarampi; Stefano Greggi; Antonella Savarese; Marco Marinaccio; Paolo Scollo; Sandro Pignata
Journal:  Int J Gynecol Cancer       Date:  2011-08       Impact factor: 3.437

2.  Thromboembolic complications in patients with clear cell carcinoma of the ovary.

Authors:  Yusuke Matsuura; Greg Robertson; Donald E Marsden; Soo-Nyung Kim; Val Gebski; Neville F Hacker
Journal:  Gynecol Oncol       Date:  2006-10-02       Impact factor: 5.482

3.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

4.  Prognostic determinants in patients with uterine and ovarian clear cell carcinoma: a SEER analysis.

Authors:  J Alejandro Rauh-Hain; Michelle Davis; Joel Clemmer; Rachel M Clark; Whitfield B Growdon; A K Goodman; David M Boruta; John O Schorge; Marcela G del Carmen
Journal:  Gynecol Oncol       Date:  2013-09-01       Impact factor: 5.482

5.  Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Authors:  Yuji Takei; Suzuyo Takahashi; Shizuo Machida; Akiyo Taneichi; Takahiro Yoshiba; Yoshifumi Takahashi; Chikako Yoshida; Yasushi Saga; Shigeki Matsubara; Hiroyuki Fujiwara
Journal:  Int J Clin Oncol       Date:  2018-04-20       Impact factor: 3.402

6.  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Authors:  T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

7.  Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO).

Authors:  Andreas du Bois; Alexander Reuss; Eric Pujade-Lauraine; Philipp Harter; Isabelle Ray-Coquard; Jacobus Pfisterer
Journal:  Cancer       Date:  2009-03-15       Impact factor: 6.860

8.  Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study.

Authors:  Scott M Eisenkop; Nick M Spirtos; Richard L Friedman; Wei-Chien Michael Lin; Albert L Pisani; Sergio Perticucci
Journal:  Gynecol Oncol       Date:  2003-08       Impact factor: 5.482

9.  Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary.

Authors:  Kayo Suzuki; Satoshi Takakura; Motoaki Saito; Asuka Morikawa; Jiro Suzuki; Kazuaki Takahashi; Chie Nagata; Nozomu Yanaihara; Hiroshi Tanabe; Aikou Okamoto
Journal:  Int J Gynecol Cancer       Date:  2014-09       Impact factor: 3.437

10.  Epidemiology of ovarian cancer: a review.

Authors:  Brett M Reid; Jennifer B Permuth; Thomas A Sellers
Journal:  Cancer Biol Med       Date:  2017-02       Impact factor: 4.248

View more
  10 in total

1.  An exploratory analysis about cycles of adjuvant chemotherapy and outcomes by substage for stage I ovarian clear cell carcinoma: a single institution retrospective study.

Authors:  Tiantian Wang; Jia Zeng; Ning Li; Rong Zhang; Yan Song; Lingying Wu
Journal:  Am J Cancer Res       Date:  2020-12-01       Impact factor: 6.166

2.  Impact of Adjuvant Chemotherapy on FIGO Stage I Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis.

Authors:  Min Yin; Jiaxin Yang; Huimei Zhou; Qian Liu; Sijian Li; Xinyue Zhang
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

3.  Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): an investigator-initiated, multicentre clinical trial-a study protocol of clinical trial.

Authors:  Ruyuan Li; Xingyu Liu; Chunyan Song; Wei Zhang; Jiahao Liu; Xiaofei Jiao; Yang Yu; Shaoqing Zeng; Jianhua Chi; Yingjun Zhao; Guanchen Ma; Yabing Huo; Ming Li; Zikun Peng; Guiling Li; Jie Jiang; Qing-Lei Gao
Journal:  BMJ Open       Date:  2022-05-24       Impact factor: 3.006

4.  A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA).

Authors:  Natalie Yl Ngoi; Valerie Heong; Samuel Ow; Wen Yee Chay; Hee Seung Kim; Chel Hun Choi; Geraldine Goss; Jeffrey C Goh; Bee Choo Tai; Diana Gz Lim; Nivashini Kaliaperumal; Veonice B Au; John E Connolly; Jae-Weon Kim; Michael Friedlander; Kidong Kim; David Sp Tan
Journal:  Int J Gynecol Cancer       Date:  2020-06-25       Impact factor: 3.437

5.  Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma.

Authors:  Qian Chen; Shu Wang; Jing-He Lang
Journal:  J Ovarian Res       Date:  2020-10-17       Impact factor: 4.234

6.  Clinical characteristics and prognosis of ovarian clear cell carcinoma: a 10-year retrospective study.

Authors:  Chenchen Zhu; Jing Zhu; Lili Qian; Hanyuan Liu; Zhen Shen; Dabao Wu; Weidong Zhao; Weihua Xiao; Ying Zhou
Journal:  BMC Cancer       Date:  2021-03-25       Impact factor: 4.430

7.  Interleukin-6 as an enhancer of anti-angiogenic therapy for ovarian clear cell carcinoma.

Authors:  Toshiyuki Seki; Nozomu Yanaihara; Jason Solomon Shapiro; Misato Saito; Junya Tabata; Ryo Yokomizo; Daito Noguchi; Takafumi Kuroda; Ayako Kawabata; Jiro Suzuki; Kazuaki Takahashi; Haruka Matsuzawa; Misayo Miyake; Masataka Takenaka; Yasushi Iida; Satoshi Yanagida; Aikou Okamoto
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

8.  Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report.

Authors:  Yu-Chien Lin; Kuo-Chang Wen; Pi-Lin Sung; Yu-Ting Chou; Phui-Ly Liew; Lin-Yu Chen; Rui-Lan Huang; Hung-Cheng Lai; Lu-Te Chang
Journal:  J Ovarian Res       Date:  2020-12-08       Impact factor: 4.234

9.  Screening of Differentially Expressed Iron Death-Related Genes and the Construction of Prognosis Model in Patients with Renal Clear Cell Carcinoma.

Authors:  Ding Wu; Zhenyu Xu; Zhan Shi; Ping Li; Huichen Lv; Jie Huang; Dian Fu
Journal:  Comput Math Methods Med       Date:  2022-08-30       Impact factor: 2.809

10.  Residual Tumor Diameter Predicts Progression After Primary Debulking Surgery of Ovarian Clear Cell Carcinoma (OCCC): Clinicopathologic Study of Stage II-IV OCCC Patients from a Single Institution.

Authors:  Yuying Shi; Mengyuan Dai; Yaxing Zhang; Yuwen Qi; Zhen Li; Hongbing Cai
Journal:  Cancer Manag Res       Date:  2021-03-04       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.